Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2022
Programm
Poster
Personen
Suche
EN
Zurück
Poster session
Poster session 5
Termin
Datum:
08.12.2022
Zeit:
16:00
–
17:00
Ort / Stream:
ePoster Terminal 5
Chair
Raffaele Ornello
L’Aquila/ IT
Programm
16:00
–
16:05
3 Min.
2 Min.
ePoster
P49
Use of anti-CGRP monoclonal antibodies in pediatric migraine: first evaluations of a phase 3, randomized, double-blind, placebo-controlled study
Fabiana Ursitti (Rome/ IT)
CGRP inhibitors in the clinic, Headache in children and adolescents
16:05
–
16:10
3 Min.
2 Min.
ePoster
P50
Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
Hasan Akcicek (Amsterdam/ NL)
CGRP inhibitors in the clinic, Migraine
16:10
–
16:15
3 Min.
2 Min.
ePoster
P51
Anti-CGRP mAbs in a difficult to treat migraine population. Efficacy and safety.
Diaz Insa Samuel (Valencia/ ES)
CGRP inhibitors in the clinic, Migraine
16:15
–
16:20
3 Min.
2 Min.
ePoster
P52
The efficacy of CGRP monoclonal antibodies – an Australian experience
Jason Ray (Melbourne/ AU)
CGRP inhibitors in the clinic, Migraine
16:20
–
16:25
3 Min.
2 Min.
ePoster
P53
Use of non-pharmacological therapies in individuals with migraine eligible for treatment with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)-signaling: a single-center cross-sectional observational study
Christopher Kjaer Cullum (Glostrup/ DK)
CGRP inhibitors in the clinic, Migraine
16:25
–
16:30
3 Min.
2 Min.
ePoster
P54
Role of Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide or Receptor (CGRP-Mabs) for Chronic Migraine Prevention: A Critical Review
Samiran Chowdhury (Lucknow/ IN)
CGRP inhibitors in the clinic, Migraine
16:30
–
16:35
3 Min.
2 Min.
ePoster
P55
Real Life Experience: Use of CGRP Inhibitors in Patients Older than 55 Years Old, are they Safe and Effective?
Maria Victoria Castro Sanchez (Malaga/ ES)
CGRP inhibitors in the clinic, Migraine
16:35
–
16:40
3 Min.
2 Min.
ePoster
P56
Real life experience and learning curve of Galcanezumab in migraine. Galca-only Consortium
Victor Obach (Barcelona/ ES)
CGRP inhibitors in the clinic, Migraine
16:40
–
16:45
3 Min.
2 Min.
ePoster
P57
Real-world Experience with Galcanezumab for the Preventive Treatment of Cluster Headache
Soo-Jin Cho (Hwaseong/ KR)
CGRP inhibitors in the clinic, Cluster headache
16:45
–
16:50
3 Min.
2 Min.
ePoster
P58
Recurrent painful ophthalmoplegic neuropathy treated with erenumab: A case report
Darija Mahović (Zagreb/ HR)
CGRP inhibitors in the clinic, Pathophysiology others than migraine and cluster
16:50
–
16:55
3 Min.
2 Min.
ePoster
P59
Investigating the Long-Term Efficacy of Calcitonin Gene Related Peptide Monoclonal Antibodies
Amira Salim (Cleveland/ US)
CGRP inhibitors in the clinic, Migraine
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz